A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use new ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...